A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Clinical trial NCT02809053 · COMPLETED
Trial details
- NCT number
- NCT02809053
- Sponsor
- Archigen Biotech Limited
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-18
- Primary completion
- 2019-07-17
- Enrollment
- 315
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.